药品名称：人生长激素注射液 商品名称：海之元? 注册分类：治疗用生物制品 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）控股子公司中山圣湘海济生物医药有限公司（以下简 称"圣湘海济"）于近日收到国家药品监督管理局（以下简称"国家药监局"）签发的《药品补充申请批准 通知书》，其产品人生长激素注射液（商品名称：海之元?）拟新增用于特发性矮身材（ISS）的适应症 补充申请已获得国家药监局的临床试验批准。现将相关情况公告如下： 一、基本情况 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品此次申请事项符合药品注册 的有关要求，批准本品开展特发性矮身材（ISS）临床试验的补充申请。 二、产品其他相关情况 受理号：CYSB2500314 申请人：中山圣湘海济生物医药有限公司 申请内容：申请增加"特发性矮身材（ISS）"适应症的临床试验 剂型：注射剂 规格：30IU/10mg/3ml/瓶 通知书编号：2026B01038 药 ...

Group 1 - Xinda Biopharmaceutical announced a strategic collaboration with Eli Lilly to advance global R&D of innovative drugs in oncology and immunology, with a total potential value of up to $88.5 billion [1] - Under the agreement, Xinda will receive an upfront payment of $350 million and may earn up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization achievements [1] - Xinda retains all rights for the projects in Greater China, while Eli Lilly obtains exclusive development and commercialization rights outside this region [1] Group 2 - Kangtai Biological announced the termination of its collaboration with AstraZeneca to establish a joint venture in the vaccine sector, which was initially planned to be set up in Beijing with a registered capital of approximately 345 million yuan (about $50 million) [2] - The decision to terminate was made due to significant market changes and increased investment risks in the vaccine industry, with no adverse impact on Kangtai's operations [2] Group 3 - China Resources Pharmaceutical announced plans to sell approximately 17.87% of its stake in Tianmai Biotechnology for a base price of about 1.42 billion yuan [3] - The sale will be conducted through a public listing, and as of the announcement date, China Resources holds less than 30% of Tianmai's shares [3] Group 4 - Dong'e Ejiao plans to invest 1.485 billion yuan to construct a health consumer goods industrial park, with a construction period of approximately 22 months [4] - The project aims to support the high-quality development of the health consumer goods business, including the production of food and health products [4] Group 5 - WuXi Biologics expects a revenue increase of approximately 16.7% to 21.79 billion yuan for the fiscal year ending December 31, 2025, with a projected profit growth of 45.3% to 5.733 billion yuan [5] - The growth is attributed to successful execution of its "Follow and Win" strategy, expansion of service offerings, and increased utilization of production capacity [7] Group 6 - Kintor Pharmaceutical signed a strategic cooperation agreement to expand its CAR-T cell therapy production base in Shanghai, with a total investment of up to 370 million yuan [8] - This initiative aligns with the commercialization of multiple CAR-T products and aims to enhance production capacity to support global competitiveness [8]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2026-017 海思科医药集团股份有限公司 第五届董事会第三十六次会议 决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 表决结果：4票同意、0票弃权、0票反对 关联董事王俊民先生回避表决，公司独立董事对该事项进行了事前审议。 公司拟与海利克斯（成都）医药科技有限公司（以下简称"海利克斯"）共同投资9,700万元人民币设立 子公司海思生物科技有限责任公司（拟用名称，以工商登记为准，以下简称"海思生物"）,其中公司投 资8,700万元人民币，占海思生物股权比例89.69%，海利克斯投资1,000万元人民币，占海思生物股权比 例10.31%； 公司拟与海利克斯共同投资4,850万元人民币设立子公司海思新元医药科技有限责任公司（拟用名称， 以工商登记为准，以下简称"海思新元"）,其中公司投资4,350万元人民币，占海思新元股权比例 89.69%，海利克斯投资500万元人民币，占海思新元股权比例10.31%。 详见同日刊登在巨潮资讯网等公司指定信息披露媒体的 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration (NMPA) for clinical trial applications of HLX43 in combination with HLX07 and Hanshuo® for the treatment of advanced solid tumors [1][2] Group 1: Clinical Trial Approvals - The clinical trial application for HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hanshuo® has been approved by NMPA [1] - The company plans to conduct the relevant clinical trials within China once conditions are met [1] Group 2: Clinical Data and Product Development - Phase 1 clinical data for HLX43 will be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and the 2025 World Lung Cancer Conference (WCLC), showing promising safety and preliminary efficacy in non-small cell lung cancer (NSCLC) and other solid tumors [2] - HLX07, an innovative biopharmaceutical targeting EGFR, has shown good safety and tolerability in a 1b/2 phase clinical study for advanced solid tumors conducted in February 2023 [2] - Hanshuo®, an innovative anti-PD-1 monoclonal antibody developed by the company, has been approved for multiple indications in mainland China, including first-line treatment for squamous NSCLC and extensive-stage small cell lung cancer [2] - The New Drug Application (NDA) for Hanshuo® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by NMPA and is under priority review [2]

Group 1 - The stock of Luye Pharma Group (博安生物) increased by nearly 5%, reaching HKD 9.12 with a trading volume of HKD 358 million as of the report time [1] - On January 21, Luye Pharma announced that its board was informed by its controlling shareholder, Luye Pharma Group, about a plan to transfer 38.5 million H-shares to the market through its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., on January 22, 2026 [1] - Luye Pharma previously acquired 98% of the shares of Luye Geneora Holding Limited, integrating its antibody drug pipeline, technology platform, and production assets, with Shandong Luye Pharmaceutical Co., Ltd. becoming the core holding entity [1] Group 2 - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Luye Pharma's shares [1] - Luye Pharma serves as a key vehicle for Luye Pharma Group's transition from traditional small molecules to biopharmaceuticals, aiding in the establishment of a dual research and development system for "chemical drugs + biological drugs" [1]

Core Insights - The cell counter industry in China is projected to reach a market size of approximately 11.24 billion yuan in 2024, with a year-on-year growth of 6.30% [1][6][8] - Traditional manual or semi-automatic counting devices are being rapidly phased out in favor of multifunctional intelligent cell analyzers that can monitor live cells and possess fluorescence analysis capabilities [1][6][8] Industry Overview - Cell counters are laboratory devices used to accurately measure the number of cells in liquid samples and analyze cell characteristics such as viability, size, morphology, and fluorescence labeling [2] - They are widely applied in fields such as biology, medicine, pharmaceuticals, cell culture, clinical diagnostics, drug screening, and cell therapy, characterized by efficiency, precision, and reduced human error [2] Industry Chain - The upstream of the cell counter industry includes raw materials and components such as lenses, filters, lasers, LED light sources, sensors, chips, and precision mechanical parts [4] - The midstream involves the production and manufacturing of cell counters, while the downstream applications span clinical diagnostics, scientific research, biopharmaceuticals, and environmental monitoring [4] Market Size - The cell counter market is a fundamental tool in the in vitro diagnostics (IVD) sector, which is expected to reach a market size of approximately 120 billion yuan in 2024, growing by 1.27% year-on-year [6] - The demand for fully automated cell counters is increasing due to the push for laboratory automation upgrades, particularly in the context of new healthcare projects [7] Key Companies - The market is characterized by a concentration of leading companies, with products from companies like Ruiwo De and Highpoint Bio being highly recognized [8] - Shenzhen Mindray Biomedical Electronics Co., Ltd. has made significant technological advancements in flow cytometry, enhancing its market position [10] Industry Development Trends 1. The technology is moving towards high integration and intelligence, evolving from mere counting tools to comprehensive intelligent analysis systems [12] 2. Market demand is shifting from general-purpose instruments to specialized solutions tailored for specific applications, leading to a more segmented market [13] 3. The industry is undergoing structural adjustments, with a focus on high-quality products and domestic alternatives gaining traction in the mid-to-high-end market [14]

Core Viewpoint - The company, Qianxin Biotech, has established itself as a leading player in the field of biopharmaceuticals, particularly focusing on autoimmune diseases, with a commitment to making high-quality therapies accessible to the general public [1][2]. Group 1: Company Overview - Qianxin Biotech was founded by Qiu Jiwan, who has decades of experience in biopharmaceutical research and development, and has grown into a national high-tech enterprise with over a hundred domestic and international patents [1]. - The company's mission emphasizes scientific innovation and the provision of affordable, high-quality therapies, aiming to meet the needs of ordinary patients [1][2]. Group 2: Product Development Strategy - The company focuses on a single domain of autoimmune diseases to concentrate resources and avoid distraction, capitalizing on the large patient base and diverse disease types within this field [1][2]. - Qianxin Biotech has successfully launched QX001S (brand name: Sailixin), the first approved biosimilar of ustekinumab in China, addressing the urgent needs of psoriasis patients [1][2]. Group 3: Innovation and Market Position - The company adopts a "combination innovation" approach, developing both biosimilars to lower drug costs and innovative drugs to overcome treatment bottlenecks, thereby making medications more accessible [2]. - Qianxin Biotech's pipeline includes QX002N and QX005N, targeting different autoimmune diseases with a differentiated strategy to build competitive advantages [3][4]. Group 4: Global Expansion and Partnerships - Recently, Qianxin Biotech entered a global exclusive collaboration with Roche for its long-acting dual antibody QX031N, receiving an upfront payment of $75 million and potential milestone payments of up to $995 million [5]. - The company aims to establish a global presence by entering overseas markets early and leveraging partnerships to accelerate product development [5]. - Qianxin Biotech's strategy includes building a global cooperation network and exploring various collaboration models to enhance its international footprint [5].

Core Insights - Jiangsu Province's Science and Technology Department has announced the first batch of major provincial science and technology projects for 2025, focusing on "Innovative Biopharmaceuticals" [1] - Suzhou leads the province with 11 selected projects, accounting for 58% of the total proposed projects, highlighting its strength and innovation in the biopharmaceutical sector [1] Project Distribution - The selected projects in Suzhou show a significant concentration, with 8 projects from Suzhou Industrial Park, and 1 each from Zhangjiagang, Suzhou High-tech Zone, and Suzhou University, indicating a cluster advantage in the biopharmaceutical industry [1] - Research directions include cancer treatment, neurological diseases, infection control, innovative drug delivery, and core industrial equipment, aiming to address clinical treatment challenges and industry development bottlenecks [1] Focus on Clinical Needs - Several projects target unmet clinical needs, focusing on cutting-edge therapies, such as the development of "safe and efficient personalized mRNA tumor vaccines" and "targeted KRAS mutation-enhanced TCR-T cell therapy drugs," providing new treatment solutions for malignant tumors, neurodegenerative diseases, and infectious diseases [1] Technological Advancements - Projects like "novel inhalation delivery system for nucleic acid drugs targeting major lung diseases" and "efficient and precise targeted nucleic acid delivery platform technology development" focus on enhancing the efficiency and industrialization of biopharmaceutical R&D across the entire drug development chain [2] - Significant progress has been made in key equipment and platform construction for biopharmaceutical R&D, with projects such as "AI-assisted design of new biopharmaceutical chromatography consumables and big data platform for separation and purification" and "high-parameter high-purity spectral flow cytometry analysis and sorting instruments" aimed at achieving self-controllable core R&D equipment and materials [2] Recognition and Future Potential - The outstanding performance of Suzhou in the provincial science and technology major projects reflects a high recognition of its current biopharmaceutical R&D capabilities and showcases its immense innovation potential in cutting-edge biopharmaceutical technologies [2] - The implementation and advancement of these projects are expected to significantly promote innovation breakthroughs and clinical transformation processes in biopharmaceutical technologies, continuously injecting new momentum into the treatment of major diseases and the development of the biopharmaceutical industry [2]

Core Viewpoint - The company, Baillie Tianheng, has received formal approval from the National Medical Products Administration (NMPA) for the clinical trial of its innovative biopharmaceutical, BL-M24D1, which is an antibody-drug conjugate (ADC) targeting relapsed or refractory hematologic malignancies and advanced solid tumors [1] Group 1 - The clinical trial approval is for the company's self-developed ADC drug, BL-M24D1, which is linked to a new generation toxin [1] - BL-M24D1 shares the same "linker + toxin" platform with other ADC drugs, BL-B16D1 and BL-M17D1, developed from the same small molecule technology platform [1] - The indications for BL-M24D1 include treatment for relapsed or refractory hematologic malignancies and advanced solid tumors [1]

Core Viewpoint - The company, Xinlitai (002294.SZ), has announced that its subsidiary, Xinlitai (Suzhou) Pharmaceutical Co., Ltd., has received acceptance for the market application of its self-developed Class 1 biological drug, "Taikasi Monoclonal Antibody Injection," from the National Medical Products Administration. The intended indications for this drug are hypercholesterolemia and mixed dyslipidemia [1]. Summary by Categories Company Developments - Xinlitai has successfully submitted a market application for its new biological drug, indicating progress in its research and development efforts [1]. Product Information - The drug "Taikasi Monoclonal Antibody Injection" targets high cholesterol levels and mixed lipid disorders, which are significant health concerns [1].